Research

New findings may enhance PARP inhibitors therapy in breast cancer

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.

The findings resulting from in vitro and mouse model studies were published in today's online issue of Nature Medicine. Study lead investigator Mien-Chie Hung, Ph.D., chair of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center, believes the study results may hold promise for future treatment of breast cancer and possibly other cancers.

"These findings may predict tumor resistance to PARP inhibitors and suggest that treatment with a combination of c-MET and PARP inhibitors may benefit patients bearing tumors with high c-MET expression who do not respond to PARP inhibition alone," said Hung.

While PARP inhibitors are still in the clinical trial phases for breast cancer, the FDA recently approved the PARP inhibitor olaparib for treatment of ovarian cancer with mutations in breast cancer genes known as BRCA.

"BRCA1 and BRCA2 play essential roles in repairing DNA double strand breaks and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition," said Hung. "Combining c-MET and PARP1 inhibitors synergized to suppress growth of breast cancer cells. Similar synergistic effects were also observed in a lung cancer mouse model."

Hung's team discovered that c-MET associates with and phosphorylates PARP1, which increases its enzymatic activity. This process essentially renders cancer cells resistant to PARP inhibition. By blocking c-MET's cancer-friendly interaction with PARP, cancer cells lose this resistance to the therapy.

"Our study findings raise the interesting possibility that cancer patients with tumors that overexpress c-MET may benefit from this combination therapy regardless of cancer type," said Hung.

MD Anderson participants in the study included Yi Du, Ph.D., Hirohito Yamaguchi, D.V.M., Ph.D., Yongkun Wei, Ph.D., Jennifer Hsu, Ph.D., Yi-Hsin Hsu, Ph.D., Wan-Chi Lin, Ph.D., Wen-Hsuan Yu, Mei-Kuang Chen, Katsuya Nakai, M.D., Ph.D., Ming-Chuan Hsu, Ph.D., Ye Sun and Chun-Te Chen, Ph.D., all of Molecular and Cellular Oncology; Paul Leonard, Ph.D., and Gilbert Lee IV, Genomic Medicine; Philip Jones, Ph.D., Institute for Applied Cancer Science; Yun Wu, M.D., Ph.D., Pathology; and Gabriel Hortobagyi, M.D., Breast Medical Oncology.

Other participating institutions included China Medical University, Taichung, Taiwan; The University of Texas Graduate School of Biomedical Sciences, Houston; Academia Sinica, Taipei; Mackay Memorial Hospital, Taipei; McGill University, Montreal; and Asia University, Taichung, Taiwan.

The study was funded by the National Institutes of Health (CA109311, CA099031 and CA16672), the Susan G. Komen For the Cure (SAC100016), Breast Cancer Research Foundation, Patel Memorial Breast Cancer Endowment Fund, The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology, International Research-Intensive Centers of Excellence in Taiwan (I-RiCE), MOST (104-2911-I-002-302), Ministry of Health and Welfare, China Medical University Hospital, and the Ting Tsung and Wei Fong Chao Research Fund.

Most Popular Now

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

FDA approves first and only single …

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) PushtronexTM system (on-body infusor with pref...

Read more

Amgen and Daiichi Sankyo announce a…

Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nin...

Read more

Boehringer Ingelheim and Lilly anno…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 83...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Losing weight lowered levels of pro…

Overweight or obese women who lost weight through diet or a combination of diet and exercise also significantly lowered levels of proteins in the blood that help certain ...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016